TAVI versus SAVR in patients at low to intermediate risk: One year outcomes of the randomized DEDICATE-DZHK6 Trial
Reported from ACC.24
Luigi Biasco interviews Moritz Seiffert about the one-year outcomes of the randomized DEDICATE-DZHK6 trial which he presented at ACC.24 in Atlanta.
TAVR was found non-inferior to SAVR in low-risk patients, showing decreased rates of death or stroke at one year. The trial supports TAVR's safety and efficacy, highlighting its less invasive nature. Further investigations will explore long-term outcomes and potential subgroup benefits.
Authors
No comments yet!